CRO/Sponsor

Danielle Mitchell, Founder of Black Women in Clinical Research, discusses how her foundation bridges the gap between minority professionals and clinical trials.

Aggressive focus by DOJ has put increased burden on stakeholders to understand their obligations and exposure.

Work across varying therapeutic areas and new technology among reasons why CROs are qualified to advance model.

Minimizing impacts through focus on employee wellness.

26 interviews conducted by Tufts CSDD found that gender-based microaggressions can negatively impact collaboration and affect retention of women employees.

Survey taken by CROs and pharma/biotech companies seeks answers in maximizing partnership.

How Clinical Research Malaysia sped up CTA turnaround using a web-based system.

In this Q&A, ACT catches up with Brian Ford, director, functional service partnership solutions, PPD Clinical Research Services, Thermo Fisher Scientific, to answer some frequently asked questions about how ILs contribute to the successful use of FSP models.

Patients reap benefits of strong collaboration in executing DCTs.

Porter discusses regulatory compliance, ATMP sponsors, and Philadelphia’s Cellicon Valley.

How pharmaceutical start-ups can mitigate risk and avoid costly hiring mistakes.

Industry provides endless methods in crafting solutions for patients.

Finalizing protocols, aligning teams, and staying engaged headline best practices.

Reminding clinical research stakeholders to reprioritize routine assessment of patient satisfaction as a primary outcome measure in patient-centric activities.

How CROs have adapted to recent challenges—and how they’ll continue to evolve in the future.

Brief history lesson sets stage for current state of CROs.

Industry must take advantage of "lessons learned."

Characterizing the long-term adoption experience of clinical technologies and capabilities—and what senior leaders can do to drive adoption within their walls.

Stakeholders from across the industry must discuss ownership to ensure effective implementation.

Examining best practices in using the functional service provider model for clinical operations, pharmacovigilance, regulatory, and other areas.

Proactive, pervasive, and strategic planning lead industry into future.

In this interview, Dave Hanaman, co-founder, president and chief commercial operator at Curavit Clinical Research discusses launching the organization at the start of the pandemic and how it operates with a commitment to designing trials with a fully virtual site.

Strong collaboration critical as trial development advances.

Technology, talent and specialization add up to a plethora of industry M&As.

A move back to in-house management of clinops could be on the horizon for sponsors.